Xencor Inc . (NASDAQ:XNCR), a biopharmaceutical company specializing in innovative therapies for immunology and oncology, ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Robert Bradway, chairman and CEO said, “Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...

Analysts' focus shifted from broader pipeline updates in Q3 to specific ... and navigating competitive pressures in core therapeutic areas.

and Novartis’ commitment to bolster its neuroscience pipeline, I speculate the companies may be seeking indications in the age-related neurological and/or inflammation therapeutic areas.

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on QURE stock, giving a Buy rating on January 27.Maximize Your ...

Furthermore, the success of Vertex's pipeline in new therapeutic areas is not guaranteed. Clinical trial failures or underwhelming efficacy data could set back the company's diversification ...